In this mouse model of multiple sclerosis (EAE Study) α4β7-blocking antibodies (DATK 32) were successful at reducing severity even though they selectively block lymphocyte entry in the gut and not the CNS (unlike tysabri/tyruko) pubmed.ncbi.nlm.nih.gov/31597098/

Performance of multiple sclerosis diagnostic criteria from different epochs. The 2024 (most recent) criteria are only 81.4% sensitive (compared to the clinician's diagnosis), but is this due to limitations of the criteria or are doctors misdiagnosing some. pubmed.ncbi.nlm.nih.gov/41776382/

YouTube video by NeuroCliff Why the Wahls Protocol Diet For MS fell from grace. #multiplesclerosis @DrBrandonBeaber

A response to my video about Dr. Terry Wahls by NeuroCliff. Why the Wahls Protocol Diet For MS fell from grace. youtu.be/qaz188PEk04?...

YouTube video by Dr. Brandon Beaber The Irony of Dr. Terry Wahls

The Irony of Dr. Terry Wahls youtu.be/Md_Bct0Szik?...

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

A fierce debate about MRI negative relapses in multiple sclerosis. 77.3% of relapses in the ULTIMATE I/II trial where were briumvi-treated group did not have brain MRI changes. These authors believes some of these events are progression or pseudorelapses. journals.sagepub.com/doi/10.1177/...

Dr. Brandon Beaber I am a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system, and I post new videos about MS every Wednesday Check out my...

Upcoming Videos:

3/4/26: The Irony of Dr. Terry Wahls
3/11/26: Kappa Free Light Chains
3/18/26: Lucid MS
3/25/26: MS Drug Overview www.youtube.com/@DrBrandonBe...

FEBRUARY 2026 LIVE STREAM NOW! ASK ME ANYTHING MULTIPLE SCLEROSIS! YouTube video by Aaron Boster MD

FEBRUARY 2026 LIVE STREAM NOW! ASK ME ANYTHING MULTIPLE SCLEROSIS! by @aaronbostermd.bsky.social www.youtube.com/live/gvsnk3F...

Diagnostic performance of central vein sign, paramagnetic rim lesion and cortical lesion in Asian patients with multiple sclerosis - PubMed Combining Select 6 or CVS number with PRL and CL, particularly in patients <50 or <70 years, provides robust diagnostic performance for MS in the Asian population.

A study on the central vein sign and paramagnetic rim lesions in Asian people with multiple sclerosis shows similar data to other ethnicities. PRL 100% specific but only present in 63% with MS. 6 or more central veins 69.1% sensitivity/98.1% specificity pubmed.ncbi.nlm.nih.gov/41755542

YouTube video by Dr. Brandon Beaber Benign Multiple Sclerosis Stories

Benign Multiple Sclerosis Stories youtube.com/shorts/FRZFF...

These researchers are using cell phone games to monitor cognitive function in multiple sclerosis www.frontiersin.org/journals/dig...

Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study - Neurology and Therapy Introduction Assessing the environmental impact on multiple sclerosis (MS) is complex because of long disease latency and potential recall bias, especially for perinatal exposures. This study aimed to...

This study found that risk of pediatric multiple sclerosis is double when both parents are smokers (crude OR 2.03, 95% CI 1.12–3.68). Data from Italy link.springer.com/article/10.1...

YouTube video by Dr. Brandon Beaber Answering Multiple Sclerosis Questions People Ask ChatGPT

Answering Multiple Sclerosis Questions People Ask ChatGPT youtu.be/TZQI8USe5p8?...

YouTube video by Dr. Brandon Beaber Answering Multiple Sclerosis Questions People Ask ChatGPT

Answering Multiple Sclerosis Questions People Ask ChatGPT youtu.be/TZQI8USe5p8?...

In this fascinating study, people with inflammatory bowel disease treated with vedolizumab (entyvio) have a lower risk of multiple sclerosis even though it only binds alpha-4-integrin in the GI tract and not the brain (unlike Tysabri) pubmed.ncbi.nlm.nih.gov/41726318/

Imuran (azathioprine)!

This drug reduced multiple sclerosis disability progression in a randomized trial but is very rarely prescribed. Can you guess what it is?

YouTube video by Aaron Boster MD Why This MS Patient Waited 5 Years for Treatment

Why This MS Patient Waited 5 Years for Treatment by @aaronbostermd.bsky.social youtu.be/SyWMRsmsBEo?...

Novantrone, no longer used in multiple sclerosis due to risks of heart failure and leukemia actually had fairly impressive data for its time in disability, relapse, and MRI outcomes.

Predictors of worsening disability in multiple sclerosis: being older, having other autoimmune diseases, more disability at baseline, low physical activity, being overweight/obese, smoking, low sun exposure (data from 3567 individuals with newly diagnosed with MS in Sweden).

YouTube video by You and Me and Multiple Sclerosis New remyelinating drug Lucid-MS soon to enter phase 2 clinical trials

New remyelinating drug Lucid-MS soon to enter phase 2 clinical trials Courtesy of Pam from the channel "You Me and Multiple Sclerosis" youtu.be/Qp8ASYzNw8o?...

YouTube video by Dr. Brandon Beaber Neuromyelitis Optica NMO Cause

Neuromyelitis Optica NMO Cause youtube.com/shorts/J0pcM...

YouTube video by runnerspace 80 Year Old Sets Indoor Mile World Record at The Armory [Full Race Replay]

80 Year old Gary Patton Old breaks the Indoor Mile World Record for the 80-84 year-old age group in 6:38.10 youtu.be/Ko7vX6Lx6Kg?...

Sport and longevity: an observational study of international athletes The human lifespan is influenced by various factors, with physical activity being a significant contributor. Despite the clear benefit of exercise on health and longevity, the association between different types of sports and lifespan is yet to be ...

Life expectancy in athletes based on a 2024 observational study looking at data between 1862 and 2002 from 183 countries across 44 sports. Pole vaulters lived the longest (8.4 years longer than the general population) pmc.ncbi.nlm.nih.gov/articles/PMC...

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1) - PubMed NCT03540485.

Very high doses of melatonin can be toxic to the liver. In this study on very high doses (300mg daily) in primary progressive multiple sclerosis, there was "liver toxicity in three of the four patients randomised to receive melatonin" pubmed.ncbi.nlm.nih.gov/41706381/

YouTube video by Dr. Brandon Beaber Multiple Sclerosis Diagnostic Criteria Explained

Multiple Sclerosis Diagnostic Criteria Explained in graphical form youtu.be/GSHrMn9w0lM?...

Tolebrutinib and the FDA - PubMed Tolebrutinib and the FDA

Did the FDA make the right decision in not approving tolebrutinib for secondary progressive multiple sclerosis? Professor Gavin Giovannoni @gavingiovannoni.bsky.social and others say "no" in this very interesting editorial. pubmed.ncbi.nlm.nih.gov/41688144/

This analysis of the French MS registry suggests the superiority of highly effective disease modifying therapies in preventing disability progression is primarily due to suppression of relapses and new MRI lesions rather than "PIRA" pubmed.ncbi.nlm.nih.gov/41689266/

In the Mazandaran province in Iran, multiple sclerosis prevalence has increased from about 1 in 500,000 in 1994 to about 1 in 800 in 2023! pubmed.ncbi.nlm.nih.gov/41689909/

Use of "platform" (left) and "highly effective" disease modifying therapies for multiple sclerosis in Saudi Arabia. www.frontiersin.org/journals/neu...

Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal | Neurology Multiple sclerosis (MS) is the most common demyelinating disease of the CNS and disproportionately affects younger individuals, yet it remains underdiagnosed and undertreated in many low and middle-in...

Multiple sclerosis in Nepal is thought to be rare (only about 15 new referrals at a tertiary training center in Kathmandu. They primarily use azathioprine and rituximab as disease modifying therapies. www.neurology.org/doi/10.1212/...